MV-4-11
Export
Established from the blast cells of a 10-year-old male with biphenotypic B-myelomonocytic leukemia.
Cell Type:
Leukocyte (unspec.)
Tissue Origin:
blood
Species:
human
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Cell Characteristics:
Suspension
Transfection Information
Lonza Optimized Protocol
Optimization Guideline
Filter:
Any Substrate
Any Platform
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols
or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our
optimization strategy
to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol
Kit
Program
Cells
Efficiency
Viable Cells
Substrate
Format
Platform
L
Q-001
2e6
29% ±4
79% ±3
Plasmid (general)
2 µg
100 µl
I/II/2b
SF
DJ-100
4e5
65% ±5
45% ±4
Plasmid (general)
0.4 µg
20 µl
4D X-Unit
SF
DJ-100
2e6
74% ±4
45% ±4
Plasmid (general)
2 µg
100 µl
4D X-Unit
Citations
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412
Categories:
Transfection
Authors:
Seedhouse CH, Hunter HM, Lloyd-Lewis B, Massip AM, Pallis M, Carter GI, Grundy M, Shang S, Russell NH
In:
Leukemia (2006) 20(12): 2130-2136
Constitutively activated FLT3 phosphorylates BAD partially through Pim-1
Categories:
Transfection
Authors:
Kim KT, Levis M, Small D
In:
Br J of Haematol (2006) 134(5): 500-509
Block of C/EBP function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
Categories:
Transfection
Authors:
Radomska HS, Basseres DS, Zheng R, Zhang P, Dayaram T, Yamamoto Y, Sternberg DW, Lokker N, Giese NA, Bohlander SK, Schnittger S, Delmotte MH, Davis RJ, Small D, Hiddemann W, Gilliland DG and Tenen DG
In:
J Exp Med (2006) 203(2): 371-81